Bezlotoxumab:A Novel Agent for the Treatment of Clostridium Difficile Infection
- VernacularTitle:治疗艰难梭菌感染新药贝洛托单抗
- Author:
Ming GE
1
;
Mei HAN
;
Wei LI
;
Huibo YANG
;
Shujun MA
Author Information
1. 唐山同济中西医结合医院药剂科 河北唐山063000
- Keywords:
Bezlotoxumab;
C. Difficile infection;
Pharmacology;
Pharmacokinetics;
Clinical studies
- From:
China Pharmacist
2017;20(11):2061-2063,2095
- CountryChina
- Language:Chinese
-
Abstract:
Bezlotoxumab is a human monoclonal antibody that can bind to C. difficile toxin B and neutralize its effects. In October 2016, bezlotoxumab was approved by the food and drug administration(FDA) to reduce the recurrence of Clostridium difficile infection (CDI) in the patients aged equal or above 18 years who are receiving antibacterial therapy. This paper introduced the pharmacology, pharmacokinetics,clinical studies,adverse reactions,interactions and medication attentions of bezlotoxumab.
